AS1411-decorated niosomes as effective nanocarriers for Ru(iii)-based drugs in anticancer strategies. Issue 33 (10th August 2018)

• Record Type: Journal Article
• Authors: Riccardi, Claudia; Fàbrega, Carme; Grijalvo, Santiago; Vitiello, Giuseppe; D'Errico, Gerardino; Eritja, Ramon; Montesarchio, Daniela
• Is Part Of: Journal of materials chemistry. Volume 6:Issue 33(2018)
• Page Start: 5368
• Page End: 5384
• Publication Date: 2018-08-10
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c8tb01563e
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : A schematic representation of AS1411/niosome_HoThyRu formulations and of the thin film hydration method, which was used for their preparation accompanied by the chemical structures of all the nanosystem components. Abstract : Niosomes are self-assembled vesicles made up of single chain non-ionic surfactants combined with appropriate amounts of cholesterol or other lipids, exploited as carriers for hydrophilic or lipophilic drugs. Compared to liposomes, niosomes are typically more stable, less expensive and, being generally obtained from synthetic surfactants, more easily derivatizable, providing vesicular structures with a higher versatility and chemical diversity. Herein, we investigated the physico-chemical and biological properties of niosomes loaded with two active ingredients, i.e. the nucleolipidic Ru(iii )-complex HoThyRu, selected as an anticancer agent, and the nucleolin-targeting AS1411 aptamer, allowing selective recognition of cancer cells. The morphology, average size, zeta potential, electrophoretic mobility, and stability over time of the functionalized niosomes were analyzed using different biophysical techniques. These formulations, tested on both cancer and normal cells, showed promising antiproliferative activity on HeLa cells, with a higher efficacy associated with the nanosystems containing both AS1411 and HoThyRu with respect to the controls. In all the tested cell lines, AS1411 proved to markedly enhance the bioactivity of the Ru(iii )-containing niosomes.